Budget Impact Analysis of the Incorporation of Ibrutinib for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia in the Brazilian Private Health Care System
Abstract
Authors
H Paiva E Asano
H Paiva E Asano
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now